Download PDF
Thromb Haemost 2018; 118(05): 914-921
DOI: 10.1055/s-0038-1641150
Stroke, Systemic or Venous Thromboembolism
Schattauer GmbH Stuttgart

Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study

Rupert Bauersachs
1   Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany
2   Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany
,
Agnes Y. Y. Lee
3   Division of Hematology, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada
,
Pieter W. Kamphuisen
4   Department of Internal Medicine, Tergooi, Hilversum, and Vascular Medicine, University Medical Center Groningen, Groningen, The Netherlands
,
Guy Meyer
5   Respiratory Unit, Hospital European Georges Pompidou, Assistance Publique-Hopitaux de Paris, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France
,
Mette S. Janas
6   LEO Pharma, Ballerup, Denmark
,
Mikala F. Jarner
6   LEO Pharma, Ballerup, Denmark
,
Alok A. Khorana
7   Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States
,
on behalf of the CATCH Investigators › Author Affiliations Funding The study was sponsored and funded by LEO Pharma. LEO Pharma had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. Medical writing support was provided by Matthew Burns VetMB, from Mudskipper Business Ltd, funded by LEO Pharma.
Further Information

Publication History

21 July 2017

09 February 2018

Publication Date:
04 April 2018 (online)

    Permissions and Reprints

Abstract

Objective This article assesses the impact of renal impairment (RI) on the efficacy and safety of anticoagulation in patients with cancer-associated thrombosis from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) study (NCT01130025).

Materials and Methods Renal function was assessed using the Modification of Diet in Renal Disease equation in patients with cancer-associated thrombosis who received either tinzaparin (175 IU/kg) once daily or warfarin for 6 months, in an open-label, randomized, multi-centre trial with blinded adjudication of outcomes. Associations between baseline RI (glomerular filtration rate [GFR] <60 mL/min/1.73m2) and recurrent symptomatic or incidental venous thromboembolism (VTE), clinically relevant bleeding (CRB), major bleeding and death were assessed using Fisher's exact test.

Results Baseline-centralized GFR data were available for 864 patients (96% of study population). RI was found in 131 patients (15%; n = 69 tinzaparin). Recurrent VTE occurred in 14% of patients with and 8% of patients without RI (relative risk [RR] 1.74; 95% confidence interval [CI] 1.06, 2.85), CRB in 19% and 14%, respectively (RR 1.33; 95% CI 0.90, 1.98), major bleeding in 6.1% and 2.0%, respectively (RR 2.98; 95% CI 1.29, 6.90) and mortality rate was 40% and 34%, respectively (RR 1.20; 95% CI 0.94, 1.53). Patients with RI on tinzaparin showed no difference in recurrent VTE, CRB, major bleeding or mortality rates versus those on warfarin.

Conclusion RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality. No differences were observed between long-term tinzaparin therapy and warfarin.

Keywords

cancer-associated thrombosis - recurrent venous thromboembolism - renal impairment - anticoagulation - tinzaparin

Authors' Contributions

All authors had full access to all of the data in the study, take responsibility for the integrity of the data and the accuracy of the data analysis, and contributed to drafting of the article. All the authors were involved in data analysis and interpretation, manuscript writing, final approval of manuscript and were accountable for all aspects of the work. Conception and design: P.W.K., A.Y.Y.L., G.M., R.B., M.S.J., A.A.K. Administrative support: M.S.J. Collection and assembly of data: M.S.J., M.F.J.


Note

The CATCH Investigators are listed in the [Supplementary Material] (available in the online version).


Supplementary Material

 

  • References

  • 1 Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. ; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 131 (01) 24-30
    CrossrefPubMedGoogle Scholar
  • 2 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 3 Wilts IT, Bleker SM, Van Es N, Büller HR, Di Nisio M, Kamphuisen PW. Safety of anticoagulant treatment in cancer patients. Expert Opin Drug Saf 2015; 14 (08) 1227-1236
    CrossrefPubMedGoogle Scholar
  • 4 Lee AYY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 5 Lee AYY, Kamphuisen PW, Meyer G. , et al; CATCH Investigators. Tinzaparin versus warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 6 Farge D, Debourdeau P, Beckers M. , et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11 (01) 56-70
    CrossrefPubMedGoogle Scholar
  • 7 Lyman GH, Khorana AA, Kuderer NM. , et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17) 2189-2204
    CrossrefPubMedGoogle Scholar
  • 8 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 9 Mandalà M, Falanga A, Roila F. ; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92
    PubMedGoogle Scholar
  • 10 Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?. Exp Hematol Oncol 2013; 2: 21
    CrossrefPubMedGoogle Scholar
  • 11 Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144 (09) 673-684
    CrossrefPubMedGoogle Scholar
  • 12 Trujillo-Santos J, Schellong S, Falga C. , et al; RIETE Investigators. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med 2013; 126 (05) 425-434.e1
    CrossrefPubMedGoogle Scholar
  • 13 van Schouwenburg IM, Mahmoodi BK, Veeger NJ, Kluin-Nelemans HC, Gansevoort RT, Meijer K. Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol 2012; 156 (05) 667-671
    CrossrefPubMedGoogle Scholar
  • 14 Monreal M, Falgá C, Valle R. , et al; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
    CrossrefPubMedGoogle Scholar
  • 15 Limdi NA, Beasley TM, Baird MF. , et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20 (04) 912-921
    CrossrefPubMedGoogle Scholar
  • 16 Janus N, Launay-Vacher V, Byloos E. , et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010; 103 (12) 1815-1821
    CrossrefPubMedGoogle Scholar
  • 17 Prins MH, Lensing AW, Brighton TA. , et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (01) e37-e46
    PubMedGoogle Scholar
  • 18 Woodruff S, Feugère G, Abreu P, Heissler J, Ruiz MT, Jen F. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis 2016; 42 (04) 494-504
    CrossrefPubMedGoogle Scholar
  • 19 Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis 2014; 7: 457-468
    PubMedGoogle Scholar
  • 20 Ferroni P, Guadagni F, Laudisi A. , et al. Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy. Oncologist 2014; 19 (05) 562-567
    CrossrefPubMedGoogle Scholar
  • 21 Lee AYY, Bauersachs R, Janas MS. , et al; CATCH Investigators. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13: 284
    CrossrefPubMedGoogle Scholar
  • 22 Levey AS, Coresh J, Greene T. , et al; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53 (04) 766-772
    CrossrefPubMedGoogle Scholar
  • 23 Levey AS, Stevens LA, Schmid CH. , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedGoogle Scholar
  • 24 Faluyi OO, Masinghe SP, Hayward RL, Clive S. Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment. Med Oncol 2012; 29 (02) 755-760
    CrossrefPubMedGoogle Scholar
  • 25 Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease 2012; 2012. Available at: http://kdigo.org/home/guidelines/ckd-evaluation-management/ . Accessed March 2018
    PubMedGoogle Scholar
  • 26 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 27 Kooiman J, den Exter PL, Cannegieter SC. , et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost 2013; 11 (11) 1968-1976
    CrossrefPubMedGoogle Scholar
  • 28 Siguret V, Pautas E, Février M. , et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84 (05) 800-804
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25 (10) 725-733
    CrossrefPubMedGoogle Scholar
  • 30 Meyer G, Marjanovic Z, Valcke J. , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
    CrossrefPubMedGoogle Scholar
  • 31 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
    CrossrefPubMedGoogle Scholar
  • 32 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines™). Cancer-associated venous thromboembolic disease. Version 1; 2015
    PubMedGoogle Scholar
  • 33 Easaw JC, Shea-Budgell MA, Wu CM. , et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol 2015; 22 (02) 144-155
    CrossrefPubMedGoogle Scholar